Serina Therapeutics Inc. (SER)
Serina Therapeutics Statistics
Share Statistics
Serina Therapeutics has 9.97M shares outstanding. The number of shares has increased by 18.05% in one year.
| Shares Outstanding | 9.97M |
| Shares Change (YoY) | 18.05% |
| Shares Change (QoQ) | 11.7% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 28,782 |
| FTD / Avg. Volume | 214.84% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -3.35 |
| PS Ratio | 0 |
| Forward PS | 7048 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Serina Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.4, with a Debt / Equity ratio of 0.42.
| Current Ratio | 2.4 |
| Quick Ratio | 2.4 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $11,833.33 |
| Profits Per Employee | $-1,233,583.33 |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -8K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -35.96% in the last 52 weeks. The beta is 0.69, so Serina Therapeutics's price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | -35.96% |
| 50-Day Moving Average | 5.02 |
| 200-Day Moving Average | 6.04 |
| Relative Strength Index (RSI) | 48.98 |
| Average Volume (20 Days) | 13,397 |
Income Statement
In the last 12 months, Serina Therapeutics had revenue of 142K and earned -14.8M in profits. Earnings per share was -1.76.
| Revenue | 142K |
| Gross Profit | -29K |
| Operating Income | -9.96M |
| Net Income | -14.8M |
| EBITDA | -9.78M |
| EBIT | -9.91M |
| Earnings Per Share (EPS) | -1.76 |
Balance Sheet
The company has 3.67M in cash and 268K in debt, giving a net cash position of 3.4M.
| Cash & Cash Equivalents | 3.67M |
| Total Debt | 268K |
| Net Cash | 3.4M |
| Retained Earnings | -44.32M |
| Total Assets | 6.72M |
| Working Capital | 3.31M |
Cash Flow
In the last 12 months, operating cash flow was -17.14M and capital expenditures -22K, giving a free cash flow of -17.16M.
| Operating Cash Flow | -17.14M |
| Capital Expenditures | -22K |
| Free Cash Flow | -17.16M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | -7014.08% |
| FCF Margin | -12083.8% |
Dividends & Yields
SER does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SER is $11, which is 93% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 93% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Mar 15, 2024. It was a backward split with a ratio of 7:250.
| Last Split Date | Mar 15, 2024 |
| Split Type | backward |
| Split Ratio | 7:250 |
Scores
| Altman Z-Score | -5.58 |
| Piotroski F-Score | 2 |